Group 1 - The core point of the news is that Boten Co., Ltd. experienced a stock price increase of 5.02%, reaching 27.38 CNY per share, with a trading volume of 583 million CNY and a turnover rate of 4.36%, resulting in a total market capitalization of 14.935 billion CNY [1] - Boten Co., Ltd. specializes in CDMO (Contract Development and Manufacturing Organization) services across chemical raw materials, chemical formulations, and biological sectors, including gene and cell therapies [1] - The company's revenue composition includes 66.81% from late-stage clinical and commercialization, 25.76% from early-stage clinical, 7.11% from emerging businesses, and 0.32% from other supplementary sources [1] Group 2 - Longsheng Fund has a significant holding in Boten Co., Ltd., with its Longsheng Transformation Upgrade Mixed Fund (001197) holding 334,100 shares, accounting for 3.93% of the fund's net value, making it the third-largest holding [2] - The Longsheng Transformation Upgrade Mixed Fund was established on April 21, 2015, with a current size of 219 million CNY, achieving a year-to-date return of 23.07% and a one-year return of 11.36% [2] - The fund manager, Wang Bingfang, has been in position for 3 years and 101 days, with the fund's total asset size at 471 million CNY, experiencing a best return of -2.92% and a worst return of -47.99% during his tenure [3]